1. Home
  2. ADPT vs ANDE Comparison

ADPT vs ANDE Comparison

Compare ADPT & ANDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • ANDE
  • Stock Information
  • Founded
  • ADPT 2009
  • ANDE 1947
  • Country
  • ADPT United States
  • ANDE United States
  • Employees
  • ADPT N/A
  • ANDE N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • ANDE Farming/Seeds/Milling
  • Sector
  • ADPT Health Care
  • ANDE Industrials
  • Exchange
  • ADPT Nasdaq
  • ANDE Nasdaq
  • Market Cap
  • ADPT 1.1B
  • ANDE 1.3B
  • IPO Year
  • ADPT 2019
  • ANDE N/A
  • Fundamental
  • Price
  • ADPT $9.03
  • ANDE $34.66
  • Analyst Decision
  • ADPT Buy
  • ANDE Buy
  • Analyst Count
  • ADPT 6
  • ANDE 3
  • Target Price
  • ADPT $9.83
  • ANDE $51.67
  • AVG Volume (30 Days)
  • ADPT 3.0M
  • ANDE 303.0K
  • Earning Date
  • ADPT 05-01-2025
  • ANDE 05-06-2025
  • Dividend Yield
  • ADPT N/A
  • ANDE 2.25%
  • EPS Growth
  • ADPT N/A
  • ANDE N/A
  • EPS
  • ADPT N/A
  • ANDE 3.17
  • Revenue
  • ADPT $189,527,000.00
  • ANDE $11,198,429,000.00
  • Revenue This Year
  • ADPT $21.20
  • ANDE $5.97
  • Revenue Next Year
  • ADPT $21.99
  • ANDE $4.31
  • P/E Ratio
  • ADPT N/A
  • ANDE $10.96
  • Revenue Growth
  • ADPT 8.61
  • ANDE N/A
  • 52 Week Low
  • ADPT $2.99
  • ANDE $31.03
  • 52 Week High
  • ADPT $10.28
  • ANDE $55.52
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 57.82
  • ANDE 38.62
  • Support Level
  • ADPT $8.38
  • ANDE $31.03
  • Resistance Level
  • ADPT $9.51
  • ANDE $38.08
  • Average True Range (ATR)
  • ADPT 0.66
  • ANDE 1.31
  • MACD
  • ADPT 0.16
  • ANDE -0.26
  • Stochastic Oscillator
  • ADPT 63.02
  • ANDE 42.75

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About ANDE Andersons Inc. (The)

Andersons Inc is a diversified company with its main focus in the agriculture sector. Its operations are segmented into Trade, Renewables, and Nutrient & Industrial. The Trade segment, which generates the majority of the revenue, is engaged in the movement of physical commodities such as whole grains, grain products, feed ingredients, and domestic fuel products, among other agricultural commodities. Geographically, the company generates the majority of its revenue from the United States and the rest from Canada, Mexico, Egypt, Switzerland, and other markets.

Share on Social Networks: